1. Home >
  2. M&A >
  3. Add-on Acquisition >
  4. United States >
  5. New York >
  6. Inhibitex Acquires FermaVir Pharmaceuticals

M&A Deal Summary

Inhibitex Acquires FermaVir Pharmaceuticals

On April 10, 2007, Inhibitex acquired life science company FermaVir Pharmaceuticals

Acquisition Highlights
  • This is Inhibitex’s 1st transaction in the Life Science sector.
  • This is Inhibitex’s 1st transaction in the United States.
  • This is Inhibitex’s 1st transaction in New York.

M&A Deal Summary
Date 2007-04-10
Target FermaVir Pharmaceuticals
Sector Life Science
Buyer(s) Inhibitex
Deal Type Add-on Acquisition

Target

FermaVir Pharmaceuticals

New York, New York, United States
FermaVir Pharmaceuticals, Inc. is a biotechnology company that develops antiviral drugs and other treatments in underserved segments of the pharmaceutical development marketplace. FermaVir’s Intellectual Property portfolio includes a number of patent applications and a worldwide exclusive license for potential new drug treatments of infectious diseases. Among FermaVir's lead drug candidates is FV-100, a potential breakthrough antiviral treatment that has demonstrated powerful inhibitory activity and may have potential therapeutic benefit for the treatment of shingles, also known as herpes zoster.

Search 214,503 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Inhibitex

Alpharetta, Georgia, United States
Category Company
Founded 1994
Sector Life Science
Employees33
DESCRIPTION

Inhibitex, Inc. is a biopharmaceutical company focused on developing products to prevent and treat serious infectious diseases. The Company’s clinical-stage pipeline includes three Phase 2 development programs: INX-189, a nucleotide polymerase inhibitor in development for the treatment of chronic hepatitis C infections, FV-100, a nucleoside inhibitor in development for the reduction of shingles-associated pain, and Aurexis, a humanized monoclonal antibody in development for the treatment of serious S. aureus bloodstream infections.

DEAL STATS #
Overall 1 of 1
Sector: Life Science M&A 1 of 1
Type: Add-on Acquisition M&A Deals 1 of 1
State: New York M&A 1 of 1
Country: United States M&A 1 of 1
Year: 2007 M&A 1 of 1
Mergr

Solution for

Product

Company

Legal